Skip to main navigation Our Science AT-527 COVID-19 About Atea Investors Careers Contact INVESTOR RELATIONS Analyst Coverage Breadcrumb Investors Stock Info Analyst Coverage Umer Raffat Evercore Eric Joseph J.P. Morgan Matthew Harrison Morgan Stanley Roanna Ruiz SVB Leerink Tim Lugo William Blair Atea Pharmaceuticals, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Atea Pharmaceuticals, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Atea Pharmaceuticals, Inc. or its management. Atea Pharmaceuticals, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. Investor FAQs RSS Feeds Email Alerts Contact IR Atea is a clinical-stage biopharmaceutical company working to address unmet medical needs through novel antiviral treatment. Atea Pharmaceuticals, Inc. 125 Summer Street Boston, MA 02110 (857) 284-8891 Copyright © 2021 By Atea Pharmaceuticals, Inc. All Rights Reserved. Privacy Policy | Terms of Use

Our Science AT-527 COVID-19 About Atea Investors Careers Contact Potential for significant clinical impact. AT-527 has a unique mechanism of action, with dual targets including chain termination (RdRp) and NiRAN inhibition, which has the potential to create a high barrier to resistance. Atea is evaluating AT-527 across multiple clinical trials that are advancing in parallel, including the global Phase 3 MORNINGSKY trial. Complementary medical intervention to vaccination similar to the influenza paradigm (Tamiflu®) Significant advantages vs antibodies: convenient for patients and healthcare workers global reach manufacture scale-up cost Highly-conserved target has potential to enable antiviral activity in the presence of multiple variants Antiviral activity against potential future coronaviruses beyond SARS-CoV-2 anticipated Key Profile Features of AT-527 Safety Generally safe and well tolerated (no drug related SAEs or discontinuations) in studies being conducted for the treatment of COVID-19 and studies conducted in HCV. Excellent Oral Bioavailability High solubility promotes rapid absorption. Convenient Delivery Designed for QD or BID (twice daily) oral administration. Manufacturing Efficient and scalable manufacture of drug product. COVID-19 Clinical Trials To learn more about our current clinical trials evaluating AT-527 for the treatment of coronavirus disease (COVID-19), please use the links below: Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19 Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) [hospitalized setting] Atea is a clinical-stage biopharmaceutical company working to address unmet medical needs through novel antiviral treatment. Atea Pharmaceuticals, Inc. 125 Summer Street Boston, MA 02110 (857) 284-8891 Copyright © 2020 By Atea Pharmaceuticals. All Rights Reserved. Privacy Policy | Terms of Use